Nashville, TN – According to filings with the U.S. Securities and Exchange Commission, Appello Pharmaceuticals is raising $15,634,465.00 in new funding. Sources indicate as part of senior management President, Brian Laden played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Appello Pharmaceuticals

Appello Pharmaceuticals is a Nashville, TN based preclinical-stage company focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson’s disease. An estimated 1 million Americans have Parkinson’s disease, a progressive brain disorder characterized by resting tremor, rigidity and slowness of movement, as well as a battery of non-motor symptoms. It is caused by the death of nerve cells in a specific brain region that produce the neurotransmitter dopamine. Licensed to Appello from Vanderbilt University, these mGlu4-specific PAMs were developed at the Vanderbilt Center for Neuroscience Drug Discovery (“VCNDD”).

To learn more about Appello Pharmaceuticals, visit http://appellopharma.com/

Contact:
Brian Laden, President
615-515-9880
brian@appellopharma.com
https://www.linkedin.com/in/brian-laden-8196614/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved